These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 17971587)
1. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Burke M; Anderson JR; Kao SC; Rodeberg D; Qualman SJ; Wolden SL; Meyer WH; Breitfeld PP; J Clin Oncol; 2007 Nov; 25(31):4909-13. PubMed ID: 17971587 [TBL] [Abstract][Full Text] [Related]
2. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. Meza JL; Anderson J; Pappo AS; Meyer WH; J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036 [TBL] [Abstract][Full Text] [Related]
3. Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma. Wolden SL; La TH; LaQuaglia MP; Meyers PA; Kraus DH; Wexler LH Cancer; 2003 Jan; 97(1):179-85. PubMed ID: 12491519 [TBL] [Abstract][Full Text] [Related]
4. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. Dantonello TM; Int-Veen C; Harms D; Leuschner I; Schmidt BF; Herbst M; Juergens H; Scheel-Walter HG; Bielack SS; Klingebiel T; Dickerhoff R; Kirsch S; Brecht I; Schmelzle R; Greulich M; Gadner H; Greiner J; Marky I; Treuner J; Koscielniak E J Clin Oncol; 2009 Mar; 27(9):1446-55. PubMed ID: 19224858 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (clinical groups III and IV). The Intergroup Rhabdomyosarcoma Study (IRS) Committee of the Cancer and Leukemia Group B Children's Cancer Study Group, Southwest Oncology Group. Raney RB; Gehan EA; Maurer HM; Newton WA; Ragab AH; Ruymann FB; Sutow WW; Tefft M Cancer Clin Trials; 1979; 2(1):19-28. PubMed ID: 391431 [TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group. Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992 [TBL] [Abstract][Full Text] [Related]
7. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486 [TBL] [Abstract][Full Text] [Related]
8. [Results of treatment of rhabdomyosarcomas (RMS) in children. A report of the Cooperative Soft Tissue Sarcoma Study (CWS-81) of the Society of Pediatric Oncology]. Treuner J; Kaatsch P; Anger Y; Seipp A; Spaar HJ; Gerein V; Suder J; Niethammer D Klin Padiatr; 1986; 198(3):208-17. PubMed ID: 3523026 [TBL] [Abstract][Full Text] [Related]
9. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? Arndt CA; Donaldson SS; Anderson JR; Andrassy RJ; Laurie F; Link MP; Raney RB; Maurer HM; Crist WM Cancer; 2001 Jun; 91(12):2454-68. PubMed ID: 11413538 [TBL] [Abstract][Full Text] [Related]
10. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. Carli M; Colombatti R; Oberlin O; Bisogno G; Treuner J; Koscielniak E; Tridello G; Garaventa A; Pinkerton R; Stevens M J Clin Oncol; 2004 Dec; 22(23):4787-94. PubMed ID: 15570080 [TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997. Blakely ML; Andrassy RJ; Raney RB; Anderson JR; Wiener ES; Rodeberg DA; Paidas CN; Lobe TE; Crist WM; J Pediatr Surg; 2003 Mar; 38(3):347-53. PubMed ID: 12632347 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087 [TBL] [Abstract][Full Text] [Related]
13. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. Wolden SL; Anderson JR; Crist WM; Breneman JC; Wharam MD; Wiener ES; Qualman SJ; Donaldson SS J Clin Oncol; 1999 Nov; 17(11):3468-75. PubMed ID: 10550144 [TBL] [Abstract][Full Text] [Related]
14. Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee. Cecchetto G; Carretto E; Bisogno G; Dall'Igna P; Ferrari A; Scarzello G; Donfrancesco A; Alaggio R; Indolfi P; Carli M Pediatr Blood Cancer; 2008 Nov; 51(5):593-7. PubMed ID: 18668515 [TBL] [Abstract][Full Text] [Related]
15. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary? Schuck A; Mattke AC; Schmidt B; Kunz DS; Harms D; Knietig R; Treuner J; Koscielniak E J Clin Oncol; 2004 Jan; 22(1):143-9. PubMed ID: 14701776 [TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297 [TBL] [Abstract][Full Text] [Related]
17. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group. Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608 [TBL] [Abstract][Full Text] [Related]
18. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood. Douglas JG; Arndt CA; Hawkins DS Eur J Cancer; 2007 Apr; 43(6):1045-50. PubMed ID: 17368885 [TBL] [Abstract][Full Text] [Related]
19. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group. Rosenberg AR; Anderson JR; Lyden E; Rodeberg DA; Wolden SL; Kao SC; Parham DM; Arndt C; Hawkins DS Eur J Cancer; 2014 Mar; 50(4):816-23. PubMed ID: 24361229 [TBL] [Abstract][Full Text] [Related]
20. Radiation therapy combined with systemic chemotherapy of rhabdomyosarcoma in children: local control in patients enrolled in the Intergroup Rhabdomyosarcoma Study. Tefft M; Lindberg RD; Gehan EA Natl Cancer Inst Monogr; 1981 Apr; (56):75-81. PubMed ID: 7029298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]